[8-K] DANAHER CORP /DE/ Reports Material Event

Rhea-AI Filing Summary

Danaher Corporation is providing an early look at its financial performance, sharing estimated results for the fourth quarter of 2025 and for full-year 2025. On January 12, 2026, the company issued a press release and presentation slides in connection with a public webcast at the J.P. Morgan Healthcare Conference on January 13, 2026. These materials, furnished under a current report, outline management’s view of recent performance and are incorporated by reference as exhibits, but are expressly designated as furnished rather than filed under securities law.

False000031361600003136162026-01-122026-01-120000313616us-gaap:CommonStockMember2026-01-122026-01-120000313616dhr:A0.2SeniorNotesDue2026Member2026-01-122026-01-120000313616dhr:A2.1SeniorNotesDue2026Member2026-01-122026-01-120000313616dhr:A1.2SeniorNotesDue2027Member2026-01-122026-01-120000313616dhr:A0.45SeniorNotesDue2028Member2026-01-122026-01-120000313616dhr:A2.5SeniorNotesDue2030Member2026-01-122026-01-120000313616dhr:A0.75SeniorNotesDue2031Member2026-01-122026-01-120000313616dhr:A1.35SeniorNotesDue2039Member2026-01-122026-01-120000313616dhr:A1.8SeniorNotesDue2049Member2026-01-122026-01-12

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

__________________

FORM 8-K

__________________

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the

Securities Exchange Act of 1934

Date of report (Date of earliest event reported): January 12, 2026

__________________

DANAHER CORPORATION

(Exact Name of Registrant as Specified in Its Charter)

__________________

Delaware						001-08089			59-1995548
(State or Other Jurisdiction of Incorporation)						(Commission File Number)			(IRS Employer Identification No.)
2200 Pennsylvania Avenue, N.W.,									20037-1701
Suite 800W
Washington,			DC
(Address of Principal Executive Offices)									(Zip Code)

202-828-0850

(Registrant’s Telephone Number, Including Area Code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

__________________

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol(s)			Name of each exchange on which registered
Common stock, $0.01 par value			DHR			New York Stock Exchange
0.200% Senior Notes due 2026			DHR/26			New York Stock Exchange
2.100% Senior Notes due 2026			DHR 26			New York Stock Exchange
1.200% Senior Notes due 2027			DHR/27			New York Stock Exchange
0.450% Senior Notes due 2028			DHR/28			New York Stock Exchange
2.500% Senior Notes due 2030			DHR 30			New York Stock Exchange
0.750% Senior Notes due 2031			DHR/31			New York Stock Exchange
1.350% Senior Notes due 2039			DHR/39			New York Stock Exchange
1.800% Senior Notes due 2049			DHR/49			New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐ 

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On January 12, 2026, in advance of a public webcast presentation at the J.P. Morgan Healthcare Conference on January 13, 2026 Danaher Corporation issued a press release regarding the Company’s estimated financial performance for the fourth quarter of 2025 and furnished pursuant to Item 2.02 of Form 8-K such press release as well as the presentation slides attached hereto, each of which is incorporated by reference herein. The presentation slides attached hereto contain certain information regarding Danaher’s estimated financial performance for 2025.

This information shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

ITEM 9.01			FINANCIAL STATEMENTS AND EXHIBITS
(c)			Exhibits:
Exhibit No.						Description
99.1						Press release — “Danaher CEO to Comment on Financial Performance”
99.1PRE						Selected Danaher Presentation Slides for J.P. Morgan Healthcare Conference on January 13, 2026
104						Cover Page Interactive Data File (formatted as inline XBRL with applicable taxonomy extension information contained in Exhibits 101)

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

									DANAHER CORPORATION
Date:			January 12, 2026			By:			/s/ Matthew R. McGrew
									Matthew R. McGrew
									Executive Vice President and Chief Financial Officer